Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
10 hedge funds and large institutions have $472K invested in Northwest Biotherapeutics, Inc. Common stock in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
15% more capital invested
Capital invested by funds: $409K → $472K (+$63K)
11% more funds holding
Funds holding: 9 → 10 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$52K |
| 2 |
GWI
Grace & White Inc
Ny,
New York
|
+$22.1K |
| 3 |
EP
Eudaimonia Partners
Winchester,
Tennessee
|
+$7K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$4.53K |
| 5 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WJWM
Williams Jones Wealth Management
New York
|
-$16.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MSAM
1
Moloney Securities Asset Management
Manchester,
Missouri
| $207K | +$52K | +34,895 | +34% |
|
|
OCG
2
Opus Capital Group
Cincinnati,
Ohio
| $66K | – | – | – |
|
|
WJWM
3
Williams Jones Wealth Management
New York
| $58K | -$16.4K | -11,000 | -22% |
|
|
GWI
4
Grace & White Inc
Ny,
New York
| $38K | +$22.1K | +14,705 | +139% |
|
|
AIP
5
Almanack Investment Partners
Wayne,
Pennsylvania
| $34K | – | – | – |
|
|
LDB
6
Lee, Danner & Bass
Nashville,
Tennessee
| $30K | – | – | – |
|
|
GG
7
Gofen & Glossberg
Chicago,
Illinois
| $19K | – | – | – |
|
|
8
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $12K | +$4.53K | +2,938 | +61% |
|
|
EP
9
Eudaimonia Partners
Winchester,
Tennessee
| $7K | +$7K | +4,700 | New |
|
|
AA
10
Ancora Advisors
Cleveland,
Ohio
| $1K | +$1K | +1,000 | New |
|
NWBO Hedge Fund Activity: Q1 2021 in Review
10 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2021, worth a combined $472K — up 15% from $409K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NWBO positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Moloney Securities Asset Management, adding an estimated $52K. The largest seller was Williams Jones Wealth Management, cutting an estimated $16.4K.
- 10 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2021, up from 9 in Q4 2020.
- Funds reported $472K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2021, up 15% quarter-over-quarter.
- 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2021 and 1 closed out, a net change of +1 holder.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2021 was Moloney Securities Asset Management, an estimated $52K added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2021 was Williams Jones Wealth Management, an estimated $16.4K sold.
Based on aggregated 13F filings for Q1 2021.